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Peritoneal Mesothelioma: An Unusual Cause of High-Protein 
Ascites
Matthew Kaspar, MD
Department of Internal Medicine, Virginia Commonwealth University Medical Center, Richmond, VA
Abstract
We present a case illustrating the workup and diagnosis of peritoneal sarcomatous mesothelioma as an unusual 
etiology of intestinal obstruction and high-protein ascites in an otherwise healthy man. This rare disorder is diag-
nosed based on immunohistochemistry, which is necessary to differentiate it from other rare sarcomatous carci-
nomas. In many cases, localized disease can be treated to cure with surgery and intraperitoneal chemotherapy. 
Advanced disease is often treated for palliation of symptoms.  
Introduction
High-protein ascites, defined as a serum albumin ascites gradient (SAAG) of less than 1.1 mg/dL, typically indi-
cates a cause of ascites not related to portal hypertension. Typical etiologies may include hypoalbuminemic states 
such as nephrotic syndrome or protein-wasting enteropathy, or any disease process associated with peritonitis, 
such as chemical irritation from pancreatitis, infectious or autoimmune serositis, or an inflammatory response as-
sociated with peritoneal carcinomatosis.1
Case Report
A 45-year-old otherwise healthy African American man presented with a chief complaint of fatigue, increasing 
abdominal girth, and unintentional weight loss of 9 kg over the past year, which rapidly worsened over the past 
3 weeks. Over the last few days, he had developed constipation, intermittent nausea, and vomiting. His history 
was significant only for employment as a laborer in construction and demolition for approximately 15 years.
Initial physical exam revealed a soft, distended abdomen with fluid wave and bulging flanks, no organomegaly, 
and active bowel sounds. Laboratory evaluation revealed only a mild elevation of alkaline phosphatase (125 
U/L). Paracentesis was performed with removal of approximately 4 L of hazy yellow fluid. The fluid had a SAAG 
of 0.4 g/dL with total protein of 5.6 g/dL. Cell count with differential was significant for 571 leukocytes with 50% 
macrophages. There were no malignant cells on fluid cytology. Abdominal CT showed massive ascites, thick-
ened loops of distal jejunum and transverse colon, ill-defined sclerotic lesions in the bodies of multiple thoracic 
vertebrae, and peritoneal enhancement concerning for carcinomatosis. Tuberculin skin testing read negative 
after 48 hours. Upper endoscopy and colonoscopy did not reveal any evidence of malignancy. 
Over the next 7 days, the patient’s abdominal pain, vomiting, and constipation progressed to a clinical picture 
consistent with small bowel obstruction. A nasogastric tube was placed with improvement in patient’s nausea 
and pain. Upper GI series did not reveal obstruction, but showed slow transit time with a long length of luminal 
narrowing and irregularities in the distal small bowel, concerning for a serosal process such as infection, neo-
plasm, or carcinomatosis (Figure 1).
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Exploratory laparoscopy to identify the cause of his small 
bowel obstruction was performed. Gross examination of the 
peritoneum revealed a frozen abdomen with bowel wall and 
peritoneal thickening in addition to areas concerning for fo-
cal tumor implant (Figure 2). Pathology from peritoneal bi-
opsies stained positive for pancytokeratin, Wilms tumor sup-
pressor gene 1 (WT1), and calretin, and negative for CD34, 
most consistent with a diagnosis of sarcomatous peritoneal 
mesothelioma. Chest CT performed after diagnosis did not 
reveal any thoracic disease.
The patient’s obstructive symptoms did not resolve. A per-
cutaneous gastrostomy tube was placed to provide durable 
decompression of the stomach, and parenteral nutrition was 
initiated. The patient began therapy with a pemetrexed and 
cisplatin regimen with a goal of symptom palliation. After 
approximately 6 months of treatment, the patient achieved 
some improvement of his obstructive symptoms, allowing 
removal of the gastrostomy tube and the reintroduction of 
oral feeding.
Discussion
Peritoneal sarcomatous mesothelioma is a rare cause of 
carcinoma-related high-protein ascites. The etiology, gen-
der distribution, pathology, natural history, and treatment 
options for mesothelioma differ substantially depending on 
the site of origin. Peritoneal mesothelioma is a rare disease, 
comprising approximately 20–30% of the 2,500 cases of 
malignant mesothelioma diagnosed in the United States 
each year.2 Outcomes are typically poor, with 5-year mortal-
ity of 29–87%, depending on stage at diagnosis.3 As with 
pulmonary mesothelioma, most peritoneal mesothelioma is 
associated with asbestos exposure.4 Though the mechanism 
by which a (presumably) inhaled carcinogen causes peri-
toneal disease is not known, it is theorized that fibers are 
inhaled, swallowed as saliva or respiratory secretions, and 
may migrate through the lumen of the bowel into the perito-
neal cavity.5
Diagnosis is challenging. Patients typically present with non-
specific symptoms such as abdominal pain (33%) and in-
creasing abdominal girth (31%), accompanied by a myriad 
of other symptoms such as weight loss, dyspnea, and night 
sweats.6 There are no tumor markers that can be used to 
make a diagnosis, and ascites fluid cytology is not a particu-
larly sensitive test.6,7 As such, peritoneal biopsy with review 
by an experienced pathologist is an essential component of 
diagnosis. Distinguishing sarcomatoid mesothelioma from 
sarcomatoid carcinoma is difficult, and a constellation of 
pathologic findings, typically with specialized immunohisto-
chemical staining, is required to make the diagnosis.8
There is currently no broadly accepted staging system for 
peritoneal mesothelioma. However, a TMN system has been 
proposed by The Peritoneal Surface Oncology Group Inter-
national (PSOGI).2 In the proposed system, tumor status is 
determined via surgical exploration, and is based on the total 
surface area of abdominal serosal surface involved as de-
fined by the Peritoneal Carcinomatosis Index (PCI).9 
For favorable histologic subtypes and localized disease, 
surgical debulking with intraperitoneal chemotherapy is the 
Figure 1. Upper GI series showing small bowel follow-through with a long 
length of small bowel luminal narrowing and fold thickening.
Figure 2. Diagnostic laparoscopy showing “frozen abdomen” with fibrotic 
peritoneum and encased bowel (black arrow), and focal areas concerning for 
tumor implant (white arrow).
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preferred method of treatment, as it offers the possibility 
of long-term survival and cure.10 Pemetrexed, with or with-
out a platinum-based agent, may be offered as a palliative 
measure for patients with disease too advanced for surgical 
therapy, providing a survival benefit ranging from 0.4 to 71 
months.11,12
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